TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03463993
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.
Study: NCT03494114
Drug: Ga-EC2115
Normalized name: Gas
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ga-EC2115 will be administered by IV injection prior to PET/CT imaging.
Study: NCT01913379
Drug: Gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01913379
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT00251225
Drug: Gleevec
Normalized name: Gleevec
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m\^2 administered IV
Study: NCT00251225
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2 administered IV on day 0
Study: NCT03005067
Drug: Carbomer 980 (1146A)
Normalized name: Carbomer 980
DrugBank: Carbomer homopolymer type C (DB14091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product containing carbomer 980 gel
Study: NCT00296491
Drug: fluticasone propionate/salmeterol (FSC)
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fluticasone propionate/salmeterol DISKUS combination
Study: NCT00296491
Drug: montelukast (MON)
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: montelukast capsule
Study: NCT00296491
Drug: fluticasone propionate (FP)
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fluticasone propionate aqueous nasal spray
Study: NCT00296491
Drug: ADVAIR DISKUS
Normalized name: Advair Diskus
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ADVAIR DISKUS
Study: NCT01934738
Drug: PF-06273340
Normalized name: PF-06273340
DrugBank: PF-06273340 (DB12269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, 100 mg TID, 14 days
Study: NCT01934738
Drug: PF-06273340
Normalized name: PF-06273340
DrugBank: PF-06273340 (DB12269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, to be decided dose, TID or titration, 14 days
Study: NCT02988869
Drug: Tiotropium/Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
Study: NCT02988869
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
Study: NCT02988869
Drug: Formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
Study: NCT01905059
Drug: monoPI - boosted lopinavir or boosted darunavir
Normalized name: Lopinavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD) This arm was stopped by the Scientific Committee on advise of the DSMB after interim analysis showing increased risk of failure for these participants. Participants are switched to standard second line triple therapy and will be followed until the last visit at week 96.
Study: NCT01905059
Drug: bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD. This arm is going on, patients will be followed on this intervention until the end of the study at week 96
Study: NCT01546649
Drug: TAP-144-SR(6M)
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03128736
Drug: Esomeprazole group
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 40mg qd
Study: NCT03128736
Drug: Dexlansoprazole group
Normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole 60mg qd
Study: NCT03645499
Drug: Topical TA-102 A
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Study: NCT03645499
Drug: Topical TA-102 B
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Study: NCT03645499
Drug: Topical TA-102 D
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Study: NCT03645499
Drug: Topical TA-102 E
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Study: NCT00857259
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg oral tablet
Study: NCT00857259
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5 mg administered by intravitreal injection
Study: NCT02439632
Drug: prulifloxacin
Normalized name: prulifloxacin
DrugBank: Prulifloxacin (DB11892)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02439632
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
Study: NCT02439632
Drug: Prulifloxacin Placebo
DrugBank: Prulifloxacin (DB11892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of prulifloxacin film-coated tablet without active components.
Study: NCT02439632
Drug: Levofloxacin Placebo
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo of levofloxacin hydrochloride tablet without active components.
Study: NCT02547766
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
Study: NCT01643226
Drug: riboflavin solution
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.12% riboflavin ophthalmic solution
Study: NCT04491357
Drug: Calcium Gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcium gluconate within 4 hours of skin closure after total thyroidectomy
Study: NCT00478049
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg oral tablet
Study: NCT00478049
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT04332848
Drug: ET
Normalized name: CET
DrugBank: Cefalotin (DB00456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
Study: NCT04332848
Drug: SGT
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
Study: NCT00103038
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00103038
Drug: Gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00484419
Drug: Colesevelam HCl
Normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: coleveselam tablets 625 mg; 6 tablets/day
Study: NCT00484419
Drug: rosiglitazone maleate
Normalized name: Rosiglitazone Maleate
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rosiglitazone tablets 4mg
Study: NCT00484419
Drug: sitagliptin phosphate
Normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sitagliptin phosphate tablets 100mg/day
Study: NCT03604341
Drug: Dronabinol 5mg Cap
Normalized name: DRONABINOL 5MG CAP
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to Dronabinol 5mg Cap and ibuprofen 800mg for pain
Study: NCT03885219
Drug: Nab-paclitaxel and S-1
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel: 120 mg/m2 d1, 8, S-1:Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 , \< 1.5 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14; repeat every 21 days.
Study: NCT03786419
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
Study: NCT01907880
Drug: Pamidronate
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90mg IV once every 4 weeks for 3 cycles
Study: NCT01570348
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01570348
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01570348
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT03071328
Drug: Isovue-M 200
Normalized name: Isovue-M 200 Solution for Injection
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
Study: NCT02011750
Drug: Sodium Valproate treatment
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
Study: NCT02138136
Drug: Lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 or 24 mcg soft capsules for oral administration
Study: NCT00003621
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003621
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03674502
Drug: ADU-1604
Normalized name: ADU-S100
DrugBank: ADU-S100 (DB14722)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-CTLA-4 monoclonal antibody
Study: NCT00093184
Drug: Angiomax (bivalirudin) anticoagulant
Normalized name: bivalirudin Injection [Angiomax]
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03738527
Drug: Tranexamic Acid 100mg/mL, 20mL topical
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Tranexamic Acid~20 mL TXA (100 mg/mL injection solution, total 2g TXA) applied topically to the mastectomy cavity for 5 minutes before wound closure
Study: NCT02281682
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
Study: NCT02281682
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
Study: NCT02281682
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: during 3 (consecutive) days once daily. Prior to treatment: curettage
Study: NCT03990480
Drug: valsartan (160 mg/d)
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group I treated with valsartan (160 mg/d, n = 100)
Study: NCT03990480
Drug: amlodipine (10 mg/d).
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group II amlodipine (10 mg/d, n = 100).
Study: NCT01849016
Drug: N-Acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01130779
Drug: Erlotinib (TARCEVA®)
Normalized name: erlotinib Oral Tablet [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150mg/day, everyday
Study: NCT00285584
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
Study: NCT00567476
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
Study: NCT00004876
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004876
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01360827
Drug: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
Normalized name: 5-FU
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
Study: NCT01360827
Drug: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
Normalized name: 5-FU
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
Study: NCT03362398
Drug: Omarigliptin 25 mg
Normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Once weekly new anti-diabetic drug approved only in Japan
Study: NCT01128582
Drug: Rozerem (ramelteon)
Normalized name: ramelteon Oral Tablet [Rozerem]
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage= take 1 tablet(8 MG) 20 min. before bedtime
Study: NCT00443482
Drug: formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03362398
Drug: Trelagliptin 100 mg
Normalized name: Trelagliptin
DrugBank: Trelagliptin (DB15323)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Once weekly new anti-diabetic drug approved only in Japan
Study: NCT00539448
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: in combination with insulin Glulisine as bolus regimen
Study: NCT00539448
Drug: insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: in combination with insulin Glargine as bolus regimen
Study: NCT03590587
Drug: 0.19 mg fluocinolone acetonide (FAc) implant
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.19 mg fluocinolone acetonide (FAc) implant
Study: NCT01761669
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00696696
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
Study: NCT00696696
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
Study: NCT00696696
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
Study: NCT00113217
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg IV on day 1 of each 14-day cycle.
Study: NCT02696031
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
Study: NCT01711970
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00266240
Drug: GK Activator (2)
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses po bid
Study: NCT04047563
Drug: Normal Saline along with standard treatment
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.
Study: NCT00597116
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00597116
Drug: Vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily oral dose
Study: NCT01376310
Drug: Docetaxel + GSK1120212
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose as defined in the dose escalation protocol.
Study: NCT01376310
Drug: Erlotinib + GSK1120212
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose as defined in the dose escalation protocol.
Study: NCT01376310
Drug: Carboplatin + GSK1120212
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose as defined in the dose escalation protocol
Study: NCT01376310
Drug: Nab-paclitaxel + GSK1120212
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dose as defined in the dose escalation protocol
Study: NCT01376310
Drug: Gemcitabine + GSK1120212
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose as defined in the dose escalation protocol
Study: NCT01376310
Drug: Everolimus + GSK1120212
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dose as defined in the dose escalation protocol
Study: NCT03275584
Drug: N-13 ammonia intravenous injection
DrugBank: Ammonia (DB11118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive two injections of N-13 ammonia, once at rest and once at stress before undergoing positron emission tomography myocardial perfusion imaging
Study: NCT03966859
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral dose, once daily for 7 days
Study: NCT00419887
Drug: Vildagliptin (LAF237)
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT03913260
Drug: Buffer Matrix (No LY3375880)
Normalized name: Matrix
DrugBank: Matrix-M (DB16369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC